A single-dose toxicity study on non-radioactive iodinated hypericin for a targeted anticancer therapy in mice

Acta Pharmacologica Sinica

Volumn 33, Issue 12, 2012, Pages 1549-1556

  Li, Jun Jie ^a,b   Cona, Marlein Miranda ^a,b   Feng, Yuan Bo ^a,b   Chen, Feng ^a,b   Zhang, Guo Zhi ^a   Fu, Xue Bin ^a   Himmelreich, Uwe ^b   Oyen, Raymond ^a   Verbruggen, Alfons ^c   Ni, Yi Cheng ^a,b  

^a DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^b KU Leuven   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Hypericin; Iodinated compound; LD50; Single dose toxicity; Targeted anticancer therapy

Indexed keywords

BIOCHEMICAL MARKER; HYPERICIN; IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL MOUSE; FEMALE; HEART; HISTOPATHOLOGY; KIDNEY; LD 50; LIVER; LUNG; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; SEROLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; FEMALE; IODINE ISOTOPES; LETHAL DOSE 50; MALE; MICE; MICE, INBRED STRAINS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; ORGAN SPECIFICITY; PERYLENE; TIME FACTORS; TOXICITY TESTS;

EID: 84870510435     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.111     Document Type: Article

References (36)

1. Hölzl J, Ostrowski E. Analysis of the Essential Compounds ofHypericum perforatum. Planta Med 1986; (6): 531
2. Tammaro F, Xepapadakis G. Plants used in phytotherapy, cosmeticsand dyeing in the Pramanda district (Epirus, North-West Greece). JEthnopharmacol 1986; 16: 167-74
3. Crak C, Radusiene J, Janulis V, Ivanauskas L. Secondary metabolitesin Hypericum perfoliatum: variation among plant par ts andphenological stages. Bot Helv 2007; 117: 29-36
4. Diasa ACP, Seabrab RM, Andradeb PB, Ferreresc F, Fernandes-Ferreiraa M. Xanthone biosynthesis and accumulation in calli andsuspended cells of Hypericum androsaemum. Plant Sci 2000; 150:93-101
5. Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics.Int J Mol Sci 2010; 11: 562-94
6. Marysael T, Ni Y, Lerut E, de Witte P. Influence of the vasculardamaging agents DMXAA and ZD6126 on hypericin distribution andaccumulation in RIF-1 tumors. J Cancer Res Clin Oncol 2011; 137:1619-27
7. Kubin A, Wierrani F, Burner U, Alth G, Grünberger W. Hypericin-thefacts about a controversial agent. Curr Pharm Des 2005; 11: 233-53
8. Agostinis P, Vantieghem A, Merlevede W, de Witte PA. Hypericin incancer treatment: more light on the way. Int J Biochem Cell Biol2002; 34: 221-41
9. Head CS, Luu Q, Sercarz J, Saxton R. Photodynamic therapy andtumor imaging of hypericin-treated squamous cell carcinoma. World JSurg Oncol 2006; 4: 87
10. Kubin A, Wierrani F, Burner U, Alth G, Grünberger W. Hypericin-thefacts about a controversial agent. Curr Pharm Des 2005; 11: 233-53
11. Ni Y, Huyghe D, Verbeke K, de Witte PA, Nuyts J, Mortelmans L, et al.First preclinical evaluation of mono-[123I]iodohypericin as a necrosisavidtracer agent. Eur J Nucl Med Mol Imaging 2006; 33: 595-601
12. Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G. Necrosis avidcontrast agents: functional similarity versus structural diversity. InvestRadiol 2005; 40: 526-35
13. Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, et al. A reviewon various targeted anticancer therapies. Target Oncol 2012; 7:69-85
14. Fonge H, Vunckx K, Wang H, Feng Y, Mortelmans L, Nuyts J, etal. Non-invasive detection and quantification of acute myocardialinfarction in rabbits using mono-[123I]iodohypericin microSPECT. EurHeart J 2008; 29: 260-9
15. Li J, Sun Z, Zhang J, Shao H, Cona MM, Wang H, et al. A dual-targetinganticancerapproach: soil and seed principle. Radiology 2011; 260:799-807
16. Van de Putte M, Wang H, Chen F, de Witte PA, Ni Y. Hypericin as amarker for determination of tissue viability after intratumoral ethanolinjection in a murine liver tumor model. Acad Radiol 2008; 15: 107-13
17. Van de Putte M, Wang H, Chen F, De Witte PA, Ni Y. Hypericin asa marker for determination of tissue viability after radiofrequencyablation in a murine liver tumor model. Oncol Rep 2008; 19: 927-32
18. Marysael T, Bauwens M, Ni Y, Bormans G, Rozenski J, de Witte P.Pretargeting of necrotic tumors with biotinylated hypericin using 123Ilabeledavidin: evaluation of a two-step strategy. Invest New Drugs 2011. doi: 10.1007/s10637-011-9778-2
19. Van de Putte M, Ni Y, De Witte PA. Exploration of the mechanismunderlyingthe tumor necrosis avidity of hypericin. Oncol Rep 2008;19: 921-6
20. Fox E, Murphy RF, McCully CL, Adamson PC. Plasma pharmacokineticsand cerebrospinal fluid penetration of hypericin in nonhumanprimates. Cancer Chemother Pharmacol 2001; 47: 41-4
21. Leuschner J. Gutachten zur experimentellen Toxikologie vonHypericum-Extract LI 160. Berlin: Lichtwer Pharma GmbH. 1995
22. Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L,Stein DS, et al. Phase I studies of hypericin, the active compound inSt. John's wort, as an antiretroviral agent in HIV-infected adults. AIDSClinical Trials Group Protocols 150 and 258. Ann Intern Med 1999;130: 510-4
23. Cui Y, Liang J, Luo Y, Wang X, Zhu Y, Shang R, et al. Acute toxicity testsof extractum hypericin. Chin J Vet Drug 2005; 39: 19-20
24. Stowell RE. Effect on tissue volume of various methods of fixation,dehydration, and embedding. Biotechnic & Histochemistry 1941; 16:67-83
25. Watanabe N, Yokoyama K, Kinuya S, Shuke N, Shimizu M, Futatsuya R,et al. Radiotoxicity after iodine-131 therapy for thyroid cancer usingthe micronucleus assay. J Nucl Med 1998; 39: 436-40
26. Narra VR, Howell RW, Harapanhalli RS, Sastry KS, Rao DV. Radiotoxicityof some iodine-123, iodine-125 and iodine-131-labeled compoundsin mouse testes: implications for radiopharmaceutical design.J Nucl Med 1992; 33: 2196-201
27. Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E,et al. Radiopharmaceutical therapy of malignant pheochromocytomawith [131I]metaiodobenzylguanidine: results from ten years ofexperience. J Nucl Biol Med 1991; 35: 269-76
28. Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman SS,Fishman EK, et al. Iodine-131 antiferrin, a new treatmentmodalityinhepatoma a radiation therapy oncology group study. J Clin Oncol1985; 3: 1573-82
29. Vincek V, Nassiri M, Nadji M, Morales AR. A tissue fixative thatprotects macromolecules (DNA, RNA, and protein) and histomorphologyin clinical samples. Lab Invest 2003; 83: 1427-35
30. Finney DJ, Ed. Probit Analysis. Cambridge, England, CambridgeUniversity Press 1952
31. Finney DJ, Stevens WL. A table for the calculation of working probitsand weights in probit analysis. Biometrika 1948; 35: 191-201
32. Song S, Xiong C, Zhou M, Lu W, Huang Q, Ku G, et al. Small-animalPET of tumor damage induced by photothermal ablation with 64Cu-bis-DOTA-hypericin. J Nucl Med 2011; 52: 792-9
33. http://www.livestrong.com/article/107004-hypericin-side-effects/34 Luksiene Z, de Witte PA. Hypericin as novel and promising photodynamictherapy tool: studies on intracellular accumulation capacityand growth inhibition efficiency. Medicina (Kaunas) 2003; 39: 677-82
34. Nagao Y, Sata M. Serum albumin and mortality risk in a hyperendemicarea of HCV infection in Japan. Virol J 2010; 7: 375
35. Onusko E. Statins and elevated liver tests: what's the fuss? J FamPract 2008; 57: 449-52
36. Li J, Cona MM, Chen F, Feng Y, Zhou L, Yu J, et al. Exploringtheranostic potentials of radioiodinated hypericin in rodent necrosismodels. Theranostics 2012; 2: 1010-9.